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Abstract Stage I–II (pN0) colorectal cancer patients are sur-
gically treated although up to 25 % will eventually die from
disease recurrence. Lymph node (LN) status is an independent
prognostic factor in colorectal cancer (CRC), and molecular
tumour detection in LN of early-stage CRC patients is associ-
ated with an increased risk of disease recurrence and poor
survival. This prospective multicentre study aimed to deter-
mine the relationship between LN molecular tumour burden
and conventional high-risk factors in stage I–II colon cancer
patients. A total of 1940 LN from 149 pathologically assessed
pN0 colon cancer patients were analysed for the amount of
tumour cytokeratin 19 (CK19) messenger RNA (mRNA) with
the quantitative reverse transcription loop-mediated isother-
mal amplification molecular assay One-Step Nucleic Acid
Amplification. Patient’s total tumour load (TTL) resulted from
the sum of all CK19 mRNA tumour copies/μL of each posi-
tive LN from the colectomy specimen. A median of 15 LN
were procured per case (IQR 12;20). Molecular positivity cor-
related with high-grade (p < 0.01), mucinous/signet ring type
(p = 0.017), male gender (p = 0.02), number of collected LN
(p = 0.012) and total LN weight per case (p < 0.01). The TTL
was related to pTstage (p = 0.01) and tumour size (p < 0.01) in
low-grade tumours. Multivariate logistic regression showed
independent correlation of molecular positivity with gender,
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tumour grade and number of fresh LN [AUC = 0.71 (95 %
CI = 0.62–0.79)]. Our results show that lymph node CK19
mRNA detection correlates with classical high-risk factors in
stage I–II colon cancer patients. Total tumour load is a quan-
titative and objective measure that may help to better stage
early colon cancer patients.
Keywords Colorectal neoplasms . Neoplasm staging .
Molecular pathology . Lymph nodes . Cytokeratin 19
Introduction
Surgical resection with no adjuvant therapy is recommended
for most stage I–II colorectal cancer (CRC) patients, except
for selected high-risk stage II patients given the significant
impact of chemotherapy on stage III disease [1, 2]. Although
there is evidence that pathological nodal staging is far from
being optimal, current NCCN guidelines are based on
haematoxylin and eosin (HE) lymph node (LN) staging,
[3–7]. Its major weakness is the limited scope of histological
LN analysis, based on a small sample provided by 2–5 μmLN
sections, which comprise less than 0.5 % of the entire LN, and
it may lead to false negative diagnoses [3, 7–9]. This may
partly explain why up to 25 % of CRC patients with histolog-
ically negative LN die from recurrent disease after a potential-
ly curative surgical resection. Some of these patients may have
had undetected LN metastases [3, 10, 11].
The use of additional techniques, i.e. immunohistochemis-
try (IHC) or reverse transcriptase polymerase chain reaction,
makes it possible to find LN tumour burden not detected with
conventional HE analysis in 25 to 50 % of CRC patients, due
to both increased sensitivity and the more extensive study than
usually permitted by histological sections [3, 6, 7, 10–17].
Although the prognostic value of LN molecular tumour
detection in early-stage CRC is controversial [14–18], there
are enough data to support the use of more sensitive (i.e.
molecular) methods of LN staging. As stated in three meta-
analyses, the molecular detection of tumour cells in regional
LN of stage I–II CRC patients is associated with an increased
risk of disease recurrence and poor survival [3, 10, 11].
Most studies have focused in dichotomic (positive-
negative) or semi-quantitative scales (isolated tumour cells
(ITC), micro- and macrometastases) to assess molecular re-
sults [8, 10, 11, 14, 15, 17, 19, 20]. The molecular assay One-
Step Nucleic Acid Amplification (OSNA; Sysmex
Corporation, Kobe, Japan) is a quantitative method which
analyses the entire LN. It amplifies cytokeratin 19 (CK19)
mRNA from LN tissue lysates using the reverse transcription
loop-mediated isothermal amplification (RT-LAMP) method
[21]. CK19 mRNA was selected among other CRC markers
showing the highest diagnostic performance and reproducibil-
ity, with 94.9–95.2 % sensitivity and 97.7–97.9 % specificity
[22]. The system has been validated for breast and colon can-
cer LN assessment, providing results comparable to extensive
histological and IHC LN analysis [8, 9, 21, 23–28]. The
amount of CK19 mRNA detected correlates with the size of
the metastatic foci [8, 9, 21, 27, 29]. It alsomakes it possible to
calculate the total tumour load (TTL) present in a given pa-
tient, by adding all CK19 mRNA copies from each positive
LN of a colectomy specimen [27, 28].
In this multicentre prospective study, we tried to correlate
the TTL, as determined by OSNA, with classical clinical and
pathologic high-risk factors, in an effort to determine whether
the TTL could be used as an additional factor to better select
stage I–II patients at risk of recurrence. Such an approach is
now widely used in the treatment of breast cancer [27, 30, 31].
Materials and methods
Study sample
This is a prospective observational study including 10 institu-
tions. Inclusion criteria were patients over 18 years old, with
primary histologically confirmed colon cancer, cN0 preoper-
ative diagnosis and positive CK19 IHC of the primary tumour.
Exclusion criteria included rectal tumours, non-invasive pTis
and pT0 tumours, positive LN on HE, synchronous tumours
or other malignancies, cN1, gross adipose tissue involvement
by the tumour, metastatic cancer, neo-adjuvant chemotherapy,
familial adenomatous polyposis, carcinomas on inflammatory
bowel disease and presence of stent-type intraluminal devices.
Study procedure
Sample processing and fresh lymph node procuring
Fresh LN procurement from the mesocolon fat was performed
within 50 min after surgical excision. When immediate LN
dissection was not possible, the surgical specimen was kept up
to 3 h in the refrigerator at 4 °C until LN dissection was done.
During the LN harvesting process, the dissection area was
kept cold by putting a thick layer of chopped ice under an
elevated metallic surface and covered with a clean filter paper
for LN dissection (Figure available at Online Resource 1a).
Microcentrifuge tubes were also kept cold by punching them
in chopped ice (Figure 2 available at Online Resource 1b). We
first detached the mesocolon fat from the colon wall with a
surgical blade. pT4 tumours corresponded to antimesenteric
serous tumour infiltration, and pT3 tumours corresponded on-
ly to specimens with minimal tumour infiltration of the
mesocolon. We then dissected one by one all LN from the
mesocolon fat using different clean areas of the surgical blade
for small LN, or changing it after each LN dissection. When a
LN was grossly suspicious of being positive, a cytology
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touch-prep was performed to confirm or discard metastasis.
Positive cases were discarded. All freshly dissected LN were
analysed by both methods, HE and OSNA, using a modified
protocol from previous studies [8, 9, 21]. Each LN was num-
bered and cut along the long axis. A central 1-mm slice was
submitted for conventional formalin-fixation paraffin-embed-
ding (FFPE) and HE analysis. The rest of the LNwas stored at
−80 °C in microcentrifuge tubes for 1 to 7 days until deferred
OSNA analysis was performed. Lymph nodes with weight
≤0.07 g (average 5.5 mm) were defined as small.
After fresh LN harvesting, the specimen was fixed over-
night in 10 % neutral buffered formalin. Then, the mesocolon
fat was re-examined for remaining LNs, which were submit-
ted only for conventional histopathology analysis.
CK19 immunohistochemistry
CK19 IHCwas performed on representative sections of all the
primary colon carcinomas to ensure reliable negative molec-
ular CK19 mRNA results. A 2-μm section of each primary
tumour was mounted on FLEX IHC microscope slides and
pre-treated in PT-LINK (Dako, Glostrup, Denmark).
Incubation for 20 min with the primary CK19 antibody
(CK19 mouse monoclonal, clone RCK108; IR615 pre-dilut-
ed. Dako) was performed in the AutostainerLink 48 (Dako).
Membranous staining with or without cytoplasm staining of
≥10 % of the tumour cells was defined as positive IHC in
colon carcinomas (Fig. 1a, b).
Pathology report and LN staging
LN staging and pathology report were performed from the
analysis of HE stains according to the AJCC/UICC TNM,
7th edition [32, 33]. Tumours ≥4 cm were defined as
large. Pathologists and clinicians were both blinded to
the OSNA results.
OSNA procedure
The OSNA method was performed at each institution follow-
ing the manufacturer’s instructions, using the protocol de-
scribed by Tsujimoto et al. [21]. Briefly, LNs were weighed,
homogenized with the lysis buffer Lynorhag (Sysmex) for
mRNA stabilization and genomic DNA precipitation. After
centrifugation for 1 min at 10,000 × g at room temperature;
a 2-μL sample of the intermediate phase was mixed with the
reagent LynoampBC (Sysmex). Analysis was performed
using the RT-LAMP isothermal amplification method with
the RD-100i automated gene-amplification system
(Sysmex). The amount of CK19mRNA amplified was detect-
ed by a change in turbidity upon precipitation of magnesium
pyrophosphate (Fig. 1c). The result was correlated to CK19
mRNA copy number/μL of the original lysate through
calibrated standard curves containing different CK19 mRNA
concentrations. In every assay, a standard positive control
sample containing 5 × 103 copies/μL of CK19 mRNA, and
a negative control sample without CK19mRNAwere used for
validation. The results were based on the number of CK19
mRNA copies/μL obtained for each LN. The cutoff value
was 250 copies/μL, based on a previous study [9].
Statistical analysis
The Fisher exact test and Pearson’s correlation coefficient
were used for testing the association between categorical or
numerical variables, respectively. The Mann-Whitney-
Wilcoxon and Kruskal-Wallis test were applied to compare
groups’ distributions. A p < 0.05 was considered statistically
significant.
Logistic regression analysis was used to predict the OSNA
outcome. The backward stepwise algorithm was used to de-
termine the best-fitting model. The classification avidity of the
model was assessed by the ROC curve and a 10-fold cross-
validation technique was applied for themodel validation. The
Cohen’s kappa was used to assess the degree of agreement
between OSNA outcome and model prediction. All analyses
were performed using R statistical environment (V.3.1.0) [34].
Results
Sample size and characteristics
We analysed 3512 LN from 211 colon cancer patients recruit-
ed in 10 hospitals between June 2012 and December 2013.We
excluded 27 non-invasive tumours (9 pT0 and 18 pTis), 34
cases with HE-positive LN, and one patient with synchronous
tumours. Finally, 149 stage I–II colon cancer patients met the
study selection criteria. All primary tumours showed positiv-
ity for CK19 IHC. Demographic, clinical, pathological, and
lymph node characteristics of the study sample and correlation
with CK19 mRNA results are summarized in Table 1 and the
study flow diagram (Fig. 2).
Lymph node features and CK19 mRNA results
Among the 2483 LN procured from 149 cases, slightly over
78 % of them were freshly isolated and submitted for OSNA
analysis (1940 fresh LN vs 543 FFPE LN). Hence, we obtain-
ed a median of 15 LN per case, of which 12 LN were analysed
by OSNA and HE.
CK19 mRNA positivity was observed in 76/149 patients
(51 %). Most of those positive cases; i.e. 80%, had only 1 to 3
positive LN. Thus, among all OSNA LN analysed, 9,8 %
(190/1940) were positive. Association analysis showed that
OSNA-positive cases harboured more freshly procured LN
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(p = 0.012) and had a higher total LN weight per case
(p < 0.01) than negative ones (Fig. 3). Regarding the size of
the freshly dissected LN, CK19 mRNA-negative LN were
significantly smaller (i.e. weight ≤0.07 g) than positive ones
(29.3 vs 15.6 %, p < 0.01).
In conclusion, fresh LN dissection did not impede an effec-
tive LN dissection and was an efficient way to obtain the
minimum number of LN required for pN assessment.
Although a substantial part of cases harboured tumour burden,
only a few LN were positive among them.
High-risk factors and CK19 mRNA detection
The pathological high-risk features of CRC that were related
to the presence of tumour CK19 mRNA in the LN were as
follows: mucinous/signet ring histological types, high histo-
logical grade and tumour size. Among demographic variables,
male gender was significantly related to OSNA positivity. No
relationship was found with pT stage, vascular invasion, mac-
roscopic tumour configuration, or other features.
High-grade tumours were significantly larger than their
low-grade counterparts (p < 0.01), with a trend between his-
tological type and tumour size (p = 0.11). The logistic regres-
sion model including OSNA results as dependent variable and
tumour size as independent variable adjusted by histological
type or grade showed a no significant relation between tumour
size and OSNA response (p = 0.26 and p = 0.15, respectively).
Themultivariate logistic regression analysis gave a reduced
predictive model for OSNA molecular output including the
independent variables gender, grade, and the number of fresh
lymph nodes (Table 2). The receiver operating characteristic
(ROC) curve was performed to test the avidity of the generat-
ed model to predict CK19 mRNA outcome, giving an
AUC = 0.71 (95%CI = 0.62–0.79).With a decision boundary
of 0.5, the sensitivity, specificity, and accuracy were 61, 68,
and 64 %, respectively. A 10-fold cross-validation was done
for the model assessment, the resulting AUC was 0.67 (95 %
CI = 0.59–0.76) (Fig. 4). Therefore, male gender, high histo-
logical grade and higher yields of LN were independent pre-
dictors of CK19 mRNA positivity.
Total tumour load
The median TTL of CK19 mRNA copies/μL among pos-
itive cases was 2015 (IQR: 940–6222.5). Cumulative TTL
showed that 29 % of patients (22/76) had more than 5000
CK19 mRNA copies/μL. Although not significant
(p = 0.18), there was a positive trend between CK19
mRNA copies/μL and pT stage; while TTL in pT1 cases
was 1280 CK19 mRNA copies/μL and 1790 CK19
mRNA copies/μL in pT2, it rose to 3080 CK19 mRNA
copies/μL in pT3 tumours (Fig. 3e). Surprisingly, the me-
dian TTL among pT4a tumours was 540 CK19 mRNA
copies/μL. This could be explained by the inclusion of
antimesenteric pT4 tumours rather than bulky tumours
with marked adipose tissue infiltration, to the scarce
amount of positive cases (5 among pT4a tumours), and
by the fact than in 3 of them less than 65 % of the LNs
were analysed by OSNA. Distribution of the cases regard-
ing their TTLs and divided by pT stage is provided as
Supplementary Table 1 in Online Resource 2. Albeit also
not significant, all OSNA positive cases with vascular
invasion had >2000 CK19 mRNA copies/μL.
In order to evaluate the distribution of the TTL, it was
categorized by quartiles and compared with classical
high-risk factors (data not shown). When stratified by tu-
mour grade, it showed that among low-grade tumours,
TTL increased with tumour stage (pT) (p = 0.01) and
tumour size (p < 0.01; rho = 0.27) (Table 3). This trend
was not observed in high-grade tumours. Taken together,
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Fig. 1 aA primary high-grade mucinous carcinoma with signet ring cells. b Positive CK19 immunohistochemistry from the same case. cAmplification
curve of CK19 mRNA from a positive LN, assessed through turbidity variation (Y-axis) over time (X-axis, minutes). (Fig. 1a, b, scale bar 250 μm)
our results show that most patients had low TTLs. These
values increased with tumour stage and followed different
distributions among low- and high-grade tumours.
Patient’s follow-up
At the time of writing of this manuscript, all patients had
a follow-up of 2 years (median 33 months, IQR 25–32.5);
8.7 % (13/149) patients recurred (3 died and 10 were alive
with metastatic disease). Four of the cases were OSNA
positive, with a median TTL of 4375 CK19 mRNA
copies/μL (range 360–47,600); 2 of the 3 dead patients
were OSNA positive.
Discussion
This study quantifies the amount of total tumour load within
the lymph nodes of stage I–II colon cancer patients, and sug-
gests that LN molecular detection of CK19 mRNA could
Table 1 Patient’s demographics and specimen characteristics and correlation with CK19 mRNA results







Cases 149 (100) 73 (49.0) 76 (51.0) –
Gender 0.02
Male 97 (65.1) 41 (42.3) 56 (57.7)
Female 52 (34.9) 32 (61.5) 20 (38.5)
Age (years)—median (IQR) 67 (61–75) 68 (61–74) 66 (61–75) 0.89
Surgical specimen characteristics
Specimen size (cm)—median (IQR) 20 (15–25) 20 (15–25) 19.5 (15–25) 0.81
Tumour size (cm)a—median (IQR) 3 (2–5) 3 (2–4) 4 (2–5.5) 0.045
Large tumours (>4 cm) 39 (26.7) 14 (38.9) 25 (64.1) 0.09
Small tumours (≤4 cm) 107 (73.3) 57 (53.3) 50 (46.7)
Tumour location 0.33
Right colon and caecum (incl. hepatic flexure) 67 (45) 37 (55.2) 30 (44.8)
Transverse colon 14 (9.4) 5 (35.7) 9 (64.3)
Left colon and sigmoid colon (incl. splenic flexure) 68 (45.6) 31 (45.6) 37 (54.4)
Macroscopic tumour configuration 0.57
Annular 8 (5.4) 5 (62.5) 3 (37.5)
Ulcerated 65 (43.6) 33 (50.8) 32 (49.2)
Polypoid 75 (50.3) 34 (45.3) 41 (54.7)
Other 1 (0.7) 1 (100) 0 (0)
Vascular invasion 0.45
No 137 (91.9) 65 (47.4) 72 (52.6)
Yes 12 (8.1) 8 (66.7) 4 (33.3)
Histological type 0.017
Adenocarcinoma 136 (91.3) 71 (52.2) 65 (47.8)
Mucinous/signet ring cell AC 13 (8.7) 2 (15.4) 11 (84.6)
Gradeb <0.01
High grade 22 (15.0) 4 (18.2) 18 (81.8)
Low grade 125 (85.0) 69 (55.2) 56 (44.8)
pT 0.19
pT1 40 (26.8) 17 (42.5) 23 (57.5)
pT2 31 (20.8) 20 (64.5) 11 (35.5)
pT3 66 (44.3) 29 (43.9) 37 (56.1)
pT4a 12 (8.1) 7 (58.3) 5 (41.7)
IQR interquartile range, AC adenocarcinoma
a In three patients, tumour size could not be assessed
b In two patients, tumour grade could not be assessed
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become an objective indicator of risk in such individuals [11,
20, 28, 35]. Stage I–II CRC is amenable to complete surgical
resection, but patients at risk of tumour recurrence are
clinically and pathologically difficult to identify [36, 37]. In
addition, cancer dissemination to LNmay occur at early stages
of tumour development [6, 38], potentially implying a poor
Fig. 3 OSNA results and correlation with LN retrieval and pT stage,
regarding number of LN retrieved (a), time spent on fresh LN search in
minutes (b) and total weight of fresh LN per case (gr) (c). OSNA positive
cases held significantly more LN due to a higher fresh LN yields. d
Shows that most cases in every pT stage held up to 3 OSNA positive
LN. e Although not significant, a trend was observed between pT stage
and TTL
Fig. 2 Study flow diagram
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prognostic impact [3, 7, 11, 15]. Thus, the assessment of the
nodal staging arises as a key factor for CRC therapeutic man-
agement [3, 10, 11].
Our findings confirm the presence of undetected nodal tu-
mour burden in early-stage colon cancer using the OSNA
method. Compared to previous studies, we have the highest
percentage of cases with CK19 mRNA detection in LN (i.e.
51%) [23–25, 28]. Discrepancies may be due to differences in
the LN collection and analysis, such as the fact that we
analysed a larger amount of LN, including all evaluable LN
by OSNA regardless of its size. Current guidelines recom-
mend evaluating at least 12 LN to achieve a reliable histolog-
ical staging [16, 32, 33, 39–42]. In compliance with them, we
obtained a median of 15 LN per patient, of which 12 were
freshly obtained and analysed by OSNA.
CRC lymph nodes are usually small, especially in early
stages of the disease, but may still contain tumour burden, as
size is not a good preoperative indicator of LN staging, or a
predictor of the presence of tumour [43–45]. Although we
identified a significant association between CK19 mRNA de-
tection and larger LN size, we found CK19 mRNA in 15.6 %
of small LN. Furthermore, the multivariate analysis of OSNA
results showed that the number of collected LN, the gender
and the histologic grade were independent predictors of
OSNA results. Our data highlights the importance of procur-
ing any identifiable LN irrespective of its size [40–42, 45–47].
Our results show that the presence of CK19 mRNA in
regional LN was associated with other classical high-risk fac-
tors such as mucinous/signet ring types, histologic high-grade,
tumour size and male gender. Moreover, it is noteworthy the
trend observed between TTL and pT stage, as pT3 had the
highest TTL (3080 CK19 mRNA copies/μL) and rate of
CK19 mRNA detection (37/66).
We also observed a different behaviour between low and
high-grade tumours, with a significant orderly increase of
TTL in regional LN with the increase of pT stage and tumour
size in low-grade tumours. This phenomenon may be
accounted for by the fact that low-grade tumours tend to fol-
low an orderly sequence of accumulation of molecular alter-
ations as they grow and acquire infiltrative proprieties [48]. In
contrast, no association was found with any assessed variables
in high-grade tumours. This may be explained by the different
molecular pathways involved in high-grade tumours and their
aggressive behaviour from the beginning [48]. Reinforcing
the importance of tumour grade in neoplastic LN spread, tu-
mour size did not correlate with CK19mRNA positivity when
stratified by grade or histological type.
The biologic significance of LN molecular tumour detec-
tion is of leading importance. Although the sole presence of
small amounts of tumour cells in regional LN does not neces-
sarily imply poor prognosis, it may indicate a yet undefined
risk of disease recurrence. This would explain why, with
Table 2 Logistic regression of clinical and histological variables related to CK19 mRNA positivity
Variables Univariate model Multivariate model
OR (95 % CI) Wald test p OR (95 % CI) Wald test p
Gender (male vs female) 2.2 (1.1–4.4) 0.026 3.1 (1.4–7.0) 0.006
Age (years) 0.99 (0.96–1.03) 0.74 – –
Tumour size 1.2 (1.0–1.4) 0.06 – –
Tumour location 0.31 – –
Transverse colon vs right colon and caecum (including hepatic flexure) 2.2 (0.7–7.9)
Left colon and sigmoid colon (including splenic flexure) vs Right colon
and caecum (including hepatic flexure)
1.4 (0.7–2.9)
Macroscopic tumour configuration 0.59 – –
Ulcerated vs annular 1.6 (0.4–8.4)
Polypoid vs annular 2.0 (0.5–10.4)
Histological type (mucinous / signet ring cell AC vs adenocarcinoma) 0.02 – –
6.0 (1.5–39.8)
Vascular invasion (yes vs no) 0.5 (0.1–1.5) 0.21 – –
Grade (high vs low) 5.4 (1.9–19.5) <0.01 4.8 (1.5–18.9) 0.013
pT 0.20 – –
pT2 vs pT1 0.4 (0.2–1.1)
pT3 vs pT1 0.9 (0.4–2.1)
pT4a vs pT1 0.5 (0.1–1.9)
Fresh LN per case weight (gr) 1.1 (1.0–1.1) <0.01 1.1 (1.0–1.2) 0.017
AC adenocarcinoma, gr grammes
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historical recurrence records of 2.5 % in pT1 N0 tumours, we
have found that almost 60 % had some CK19 mRNA tumour
burden in their LN [11, 49]. In this context, low TTLs may
have no further biologic consequences, but large amounts of
tumour burden within the LN may imply higher odds of re-
currence [7, 27]. A study using RT-qPCR detection of
Guanylyl cyclase C (GUCY2C) by RT-qPCR found 87.5 %
patients with positive LN, although only 20.9 % developed
recurrent disease [7].
Quantifying the amount of tumour burden, not just the
presence or absence of tumour, in regional lymph nodes is
therefore important in prognosticating from molecular results,
as has been stated in CRC [3, 7, 11, 20, 35] and breast cancer
[27, 31]. It should be highlighted that whereas the median
TTL of our cohort was 2015 CK19 mRNA copies/μL, values
up to 15,000 CK19 mRNA copies/μL have been recently set
in breast cancer sentinel LN as clinically relevant to predict
additional axillary LN metastases [27]. Some authors have
also demonstrated the relationship between the amount of
metastatic tumour and prognosis, stressing the importance of
distinguishing ITC from micrometastases [7, 11, 23, 24, 50].
Two novel Japanese multicentre studies stress the need to
stratify molecular outcomes in LN assessment. The first one
addresses that TTL significantly increases with pN stage [28]
and suggests it as a potential staging technique. The second
one has shown the correlation of LN micrometastasis volume,
measured by qRT-PCR for CEA mRNA, as a predictor of
Table 3 Total tumour load
distribution in high and low-grade
tumours
pT CK19 mRNA copies/μL per case n (%) Total n (%) p value
<1000 <2000 <6000 ≥6000
All cases 0.246
pT1 8 (34.8)a 6 (26.1) 6 (26.1) 3 (13.0) 23 (100)
pT2 1 (9.1) 5 (45.4) 3 (27.3) 2 (18.2) 11 (100)
pT3 9 (24.3) 6 (16.2) 8 (21.6)a 14 (37.8) 37 (100)
pT4a 2 (40.0) 1 (20.0) 2 (40.0) 0 (0.0) 5 (100)
Total 20 (26.3) 18 (23.7) 19 (25) 19 (25) 76 (100)
High grade 0.61
pT1 1 (20.0) 1 (20.0) 2 (40.0) 1 (20.0) 5 (100)
pT2 1 (50.0) 0 (0.0) 0 (0.0) 1 (50.0) 2 (100)
pT3 1 (12.5) 4 (50.0) 1 (12.5) 2 (25.0) 8 (100)
pT4a 1 (33.3) 0 (0.0) 2 (66.7) 0 (0.0) 3 (100)
Total 4 (22.2) 5 (27.8) 5 (27.8) 4 (22.2) 18 (100)
Low grade 0.01
pT1 6 (35.3) 5 (29.4) 4 (23.5) 2 (11.8) 17 (100)
pT2 0 (0.0) 5 (55.6) 3 (33.3) 1 (11.1) 9 (100)
pT3 8 (28.6) 2 (7.1) 6 (21.4) 12 (42.9) 28 (100)
pT4a 1 (50.0) 1 (50.0) 0 (0.0) 0 (0.0) 2 (100)
Total 15 (26.8) 13 (23.2) 13 (23.2) 15 (26.8) 56 (100)
a In two patients, tumour grade could not be assessed
Fig. 4 ROC curve of the multivariate logistic regression model for
OSNA results including gender, grade and the number of fresh lymph
nodes as variables predicting molecular positivity. Continuous line: All
data (0.71 (95 % CI = 0.62–0.79);Dashed line: 10-fold CV (AUC = 0.67
[95 % CI = 0.59–0.76])
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recurrence in stage II patients [51]. In addition to these find-
ings, we have found that TTL unveils distinct progression
patterns in low- and high-grade neoplasms.
Our study has some drawbacks; firstly, a follow-up period of
2 years is a limited time to establish the amount of CK19
mRNA copies that would have clinical significance; thus, the
OSNA results could not be correlated with prognosis.
Nevertheless, this study was not designed to determine the role
of the molecular results as a prognostic factor, but to find out
whether the OSNA results correlated with other classical CRC
high-risk factors. Secondly, in order to evaluate the histological
high-risk factors, we focused on histologically pN0 specimens.
To assess the potential predictive value of the TTL, colectomy
specimens should be studied regardless of their LN status, thus
comparing histological and molecular evaluation methods and
their ability to predict disease recurrence.
In conclusion, this study identifies the presence of unde-
tected tumour burden in LN of early colon cancer patients.
TTL correlates with other CRC classical high-risk factors
and may be placed among them. We thereby support CK19
mRNATTL as a fast and reliable approach to help better stage
early colon cancer. Long-term follow-up and validation stud-
ies are needed to obtain a predictive prognostic scale for stage
I–II colon cancer patients based on the patient’s TTL.
AC, adenocarcinoma; AUC, area under the curve; CK19,
cytokeratin 19; CRC, colorectal cancer; FFPE, formalin-
fixation paraffin-embedding; HE, Haematoxylin and Eosin;
IHC, immunohistochemistry; IQR, interquartile range; ITC,
isolated tumour cells; LN, lymph node; OSNA, one-step
nucleic acid amplification; pT, tumour stage; ROC, receiver-
operator characteristic; RT-LAMP, reverse transcription loop-
mediated isothermal amplification; TTL, total tumour load
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